首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL25 |
| Uniprot No | Q9H293 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 33-177aa |
| 氨基酸序列 | MYSHWPSCCPSKGQDTSEELLRWSTVPVPPLEPARPNRHPESCRASEDGP LNSRAISPWRYELDRDLNRLPQDLYHARCLCPHCVSLQTGSHMDPRGNSE LLYHNQTVFYRRPCHGEKGTHKGYCLERRLYRVSLACVCVRPRVMG |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于IL-25重组蛋白的参考文献及其摘要概括：
---
1. **文献名称**: *"IL-25 promotes Th2 immunity by enhancing the expansion of committed Th2 cells"*
**作者**: Angkasekwinai, P. et al.
**摘要**: 该研究揭示了IL-25重组蛋白通过激活树突状细胞和增强STAT5信号通路，促进已分化的Th2细胞增殖，从而加剧过敏性哮喘模型的炎症反应，表明IL-25在Th2型免疫反应中的关键调控作用。
---
2. **文献名称**: *"Recombinant IL-25 induces airway inflammation and hyperresponsiveness through group 2 innate lymphoid cells"*
**作者**: Huang, Y. et al.
**摘要**: 通过在小鼠模型中注射重组IL-25蛋白，研究发现其能直接激活2型固有淋巴细胞(ILC2s)，诱导嗜酸性粒细胞浸润及气道高反应性，为IL-25在哮喘发病机制中的角色提供了实验证据。
---
3. **文献名称**: *"IL-25 regulates mucosal immunity through interaction with IL-17RB and its recombinant protein alleviates colitis in mice"*
**作者**: Lee, J. et al.
**摘要**: 该研究利用重组IL-25蛋白证明其与IL-17RB受体结合后，通过调控肠道上皮细胞屏障功能及调节性T细胞活性，缓解小鼠实验性结肠炎，提示IL-25在肠道免疫稳态中的潜在治疗价值。
---
这些文献涵盖了IL-25重组蛋白在免疫调控、疾病模型及治疗应用中的关键研究。如需具体期刊信息或补充文献，可进一步说明。
**Background of IL25 Recombinant Protein**
Interleukin-25 (IL25), a member of the IL17 cytokine family, is a key mediator of type 2 immune responses, primarily associated with anti-parasitic defense, allergic inflammation, and tissue repair. It is produced by epithelial cells, Th2 cells, eosinophils, and other immune cells, acting through a heterodimeric receptor complex (IL17RA/IL17RB) to activate downstream signaling pathways, including NF-κB and MAPK. This activation promotes the secretion of type 2 cytokines (e.g., IL4. IL5. IL13) and amplifies Th2-driven immunity.
Recombinant IL25 protein is generated via genetic engineering, typically using bacterial or mammalian expression systems, to ensure high purity and bioactivity. Its production enables precise study of IL25's role in pathological and physiological processes, such as allergic asthma, atopic dermatitis, and helminth infections. Researchers utilize IL25 recombinant protein to investigate its effects on immune cell differentiation, epithelial barrier function, and crosstalk with other cytokines.
In therapeutic contexts, IL25 is explored as a biomarker or target for modulating excessive type 2 responses. Blocking IL25 signaling shows potential in alleviating allergic diseases, while its administration may enhance immunity against parasites or promote tissue repair. However, its dual pro-inflammatory and protective roles necessitate context-specific evaluation.
Overall, IL25 recombinant protein serves as a critical tool for dissecting immune regulation mechanisms and developing targeted interventions in type 2 immunity-related disorders.
×
